The effects of statin and fibrate on lowering small dense LDL-cholesterol in hyperlipidemic patients with type 2 diabetes

Journal of Atherosclerosis and Thrombosis

Volumn 14, Issue 3, 2007, Pages 128-132

  Tokuno, Anna ^a   Hirano, Tsutomu ^a   Hayashi, Toshiyuki ^a   Mori, Yusaku ^a   Yamamoto, Takeshi ^a   Nagashima, Masaharu ^a   Shiraishi, Yuji ^a   Ito, Yasuki ^b   Adachi, Mitsuru ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b DENKA COMPANY LIMITED   (Japan)

Author keywords

Fenofibrate; Pitavastatin; Small dense LDL cholesterol; Type 2 diabetes

Indexed keywords

ANTILIPEMIC AGENT; FENOFIBRATE; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN INHIBITOR; PRAVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; COMPARATIVE STUDY; FEMALE; HUMAN; HYPERLIPIDEMIA; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PRAVASTATIN; PROCETOFEN; TRIGLYCERIDES;

EID: 34548020337     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.14.128     Document Type: Article

References (18)

1. Berneis KK and Krauss RM: Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res, 2002; 43:1363-1379
2. Lamarche B, Lemieux I, and Després JP: The small dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metabolism, 1999; 25:199-211
3. Gardner CD, Fortmann SP, and Krauss RM: Association of small dense low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA, 1996; 276:875-881
4. Koba S, Hirano T, Yoshino G, Sakai K, Sakaue T, Adachi M, and Katagiri T. Remarkably high prevalence of small dense low-density lipoprotein in Japanese men with coronary artery disease, irrespective of the presence of diabetes. Atherosclerosis, 2002; 160:249-256
5. Koba S, Hirano T, Kondo T, Shibata M, Suzuki H, Murakami M, Geshi E, and Katagiri T. Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart diseases. Am Heart J, 2002; 144:1026-1035
6. Nichols AV, Krauss RM, and Musliner TA: Nondenaturing polyacrylamide gradient gel electrophoresis. Methods Enzymol, 1986; 128:417-433
7. Zambon A, Hokanson JE, Brown BG, and Brunzell JD: Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation, 1999; 99:1959-1964
8. Hirano T, Ito Y, Saegusa H, and Yoshino G: A novel and simple method for quantification of small dense LDL. J Lipid Res, 2003; 44:2193-2201
9. Hirano T, Ito Y, and Yoshino G: Measurement of small dense low-density lipoprotein particles. J Atheroscler Thromb, 2005; 12:67-72
10. Hirano T, Ito Y, Koba S, Toyoda M, Ikejiri A, Saegusa H, Yamazaki J, and Yoshin G: Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol, 2004; 24:558-563
11. Bradley WA, Hwang SL, Karlin JB, Lin AH, Prasad SC, Gotto AM Jr, and Gianturco SH: Low-density lipoprotein receptor binding determinants switch from apolipoprotein E to apolipoprotein B during conversion of hypertriglyceridemic very-low-density lipoprotein to low-density lipoproteins. J Biol Chem Dec, 1984; 259:14728-14735
12. Packard CJ and Shepherd J: Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol, 1997; 17:3542-3556
13. Yoshino G, Hirano T, and Kazumi T: Treatment of small dense LDL. J Atheroscler Thromb, 2002; 9:266-275
14. Saito Y, Teramoto T, Yamada N, Itakura H, Hata Y, Nakaya N, Mabuchi H, Tsushima M, Sasaki J, Ogawa N, and Goto Y: Clinical efficacy of NK-104 (Pitavastatin), a new synthetic HMG-CcA reductase inhibitor, in the doswe finding, double blind, three-group comparative study. Rishou Iyaku, 2001; 17:829-855 (Summary in English)
15. Sone H, Takahashi A, Shimano H, Ishibashi S, Yoshino G, Morisaki N, Saito Y, Kawazu S, Teramoto T, Fujita T, Shiba T, Iwamoto Y, Kuzuya N, Akanuma Y, and Yamada N: HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sci, 2002; 71:2403-2412
16. Vakkilainen J, Steiner G, Ansquer JC, Aubin F, Rattier S, Foucher C, Harnsten A, and Taskinen MR, on behalf of the DAIS group: Relationships between low-density lipo-protein particle size, plasma lipoproteins, and progression of coronary artery disease. The Diabetes Atherosclerosis Intervention Study (DAIS). Circulation, 2003; 107:1733-1737
17. Milosavljevic D, Griglio S, Le Naour G, and Chapman MJ: Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages. Atherosclerosis, 2001; 155:251-260
18. Hirano T, Kazumi T, and Yoshino G: Long-term efficacy of bezafibrate on reducing small dense LDL by its hypotriglyceridemic action. Curr Ther Res, 2000; 61:127-136